Loading clinical trials...

TERMINATEDPHASE3

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

NCT04308395•Sol-Gel Technologies, Ltd.

View on ClinicalTrials.gov

Summary

This is a multicenter, open label extension study evaluating the safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. The subject must have completed PellePharm Study Pelle-926-201 or Pelle-926-301.
•2. Study Pelle-926-301 subjects must have completed the End of Treatment Visit in Study 301, prior to the Screening Visit in this study. They must also complete all Study 301 related procedures prior to the Baseline Visit of this study.
•3. The subject must be willing to abstain from application of a non-study topical medication (prescription or over the counter) to facial skin for the duration of the trial except as prescribed by the Investigator. Moisturizers and emollients are allowed. Subjects will be encouraged to use their preferred sunscreen with a sunscreen protection factor (SPF) of at least 30 daily on all exposed skin sites.
•4. Female subjects must have a negative pregnancy test. For Study 301 subjects a negative serum pregnancy test result from Study 301 is acceptable if the test was done within 7 days of the Screening Visit of this study.
•5. If the subject is a woman of child bearing potential (WOCBP), she must be willing to use birth control methods which may be considered highly effective. Hormonal contraception must be supplemented with a barrier method (preferably condom). Birth control must start prior to Baseline, continue through the duration of the study, and for 30 days after last application of investigational product (IP).
•6. If the subject is a male with a female sex partner who is a WOCBP, the subject must be willing to use condoms, even after a vasectomy, starting prior to Baseline, through the duration of the study, and for at least 3 months after the last application of IP.
•7. The subject is willing for all facial BCCs to be evaluated and follow treatment recommendations made only by the Investigator.
•8. The subject is willing to forego treatment of facial BCCs with anything other than the study IP except when the Investigator believes that delay of treatment of a BCC potentially might compromise the health of the subject. In such instances, the only other allowed form of treatment is surgical.

Exclusion Criteria

•1. The subject has used topical treatment to the face or systemic therapies that might interfere with the evaluation of the study IP.
•2. The subject has current, recent (within five half lives of the experimental drug or if half life not known, within the past 6 months prior to the Screening Visit), or planned (while enrolled in this study) participation in an experimental drug study (excluding Study 301).
•3. The subject is a WOCBP who is unwilling or unable to comply with pregnancy prevention measures.
•4. The subject is pregnant or breastfeeding.

Locations (37)

PellePharm Investigative Site

Fremont, California, United States

PellePharm Investigative Site

Newport Beach, California, United States

Yale University

New Haven, Connecticut, United States

Pellepharm Investigative Site

Miami, Florida, United States

PellePharm Investigative Site

Ormond Beach, Florida, United States

PellePharm Investigative Site

Chicago, Illinois, United States

Laser & Skin Surgery Center of Indiana

Indianapolis, Indiana, United States

Pellepharm Investigative Site

Ann Arbor, Michigan, United States

University of Minnesota

Minneapolis, Minnesota, United States

Saint Louis University

St Louis, Missouri, United States

Key Dates

Start Date

June 3, 2020

Primary Completion Date

July 14, 2021

Completion Date

July 14, 2021

Last Updated

September 24, 2024

Enrollment

108

ACTUAL participants

Conditions

Basal Cell Nevus Syndrome

Interventions

Patidegib Topical Gel, 2%

DRUG

Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling

NCT06330350

Quality of LifeIchthyosis+8 more

View study

ENROLLING_BY_INVITATION

Reproductive Options in Inherited Skin Diseases

NCT06330324

IchthyosisPalmoplantar Keratoses+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 24, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

Inclusion Criteria

Exclusion Criteria

Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling

Reproductive Options in Inherited Skin Diseases

To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome